|
A Study of Retrovir and Epivir Alone or in Combination with 141W94 in HIV-Infected Patients Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on A Study of Retrovir and Epivir Alone or in Combination with 141W94 in HIV-Infected Patients conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. A Study of Retrovir and Epivir Alone or in Combination with 141W94 in HIV-Infected Patients Clinical research trials and A Study of Retrovir and Epivir Alone or in Combination with 141W94 in HIV-Infected Patients healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including A Study of Retrovir and Epivir Alone or in Combination with 141W94 in HIV-Infected Patients. A Study of Retrovir and Epivir Alone or in Combination with 141W94 in HIV-Infected Patients Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a A Study of Retrovir and Epivir Alone or in Combination with 141W94 in HIV-Infected Patients clinical trial. Test subjects typically receive the most effective healthcare possible for their A Study of Retrovir and Epivir Alone or in Combination with 141W94 in HIV-Infected Patients condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of Retrovir and Epivir Alone or in Combination with 141W94 in HIV-Infected Patients  A Study of Retrovir and Epivir Alone or in Combination with 141W94 in HIV-Infected Patients
A Study of Retrovir and Epivir Alone or in Combination with 141W94 in HIV-Infected Patients
For Condition: HIV Infections
Status: Completed
Sponsor(s): Glaxo Wellcome ,
Synopsis: The purpose of this study is to see if it is safe and effective to add 141W94 to an anti-HIV regimen that includes retrovir plus epivir.
Details: This is a double-blind, placebo-controlled, two-arm study comparing treatment with a triple regimen consisting of 141W94, retrovir, and epivir and a double regimen consisting of retrovir and epivir.
Eligibility:
Study Type: Interventional, Treatment, Parallel Assignment, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have: - HIV-positive status. - Screening viral load >= 10,000 copies/mm3 14 days prior to entry. - CD4+ cell counts >= 200 cells/mm3 14 days prior to entry. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Clinical diagnosis of AIDS (CDC 1993 Classification C). Concurrent Medication: Excluded: Terfenadine, astemizole, cisapride, triazolam, medazolam, and ergotamine/dihydroergotamine-containing regimens. Patients with the following prior conditions are excluded: Clinically relevant hepatitis in the previous 6 months. Prior Medication: Excluded: - Greater than 4 weeks of any nucleoside antiretroviral therapy. - Previous therapy with an HIV protease inhibitor. - Cytotoxic chemotherapeutic agents within 4 weeks prior to entry. - Immunomodulating agents within 3 months prior to entry. Prior Treatment: Excluded: Radiotherapy within 4 weeks prior to entry. Risk Behavior: Excluded: Current alcohol or illicit drug use that may interfere with the patient's ability to comply with the dosing schedule or protocol evaluations.
Total Enrollment: 290
Location and Contact Information:
Community Research Initiative of Central Florida
Maitland, Florida, 32751
United States
Univ of Miami School of Medicine
Miami, Florida, 33136
United States
Dr Bruce Rashbaum
Washington D.C., District of Columbia, 20037
United States
Community Research Initiative of New England
Brookline, Massachusetts, 02445
United States
Community Research Initiative of South Florida
Coral Gables, Florida, 33146
United States
Chicago Ctr for Clinical Research
Chicago, Illinois, 60610
United States
Methodist Hosp
Memphis, Tennessee, 38104
United States
Saint Vincent's AIDS Ctr
New York City, New York, 10011
United States
Pacific Oaks Research
Beverly Hills, California, 90211
United States
Additional Information:
Study ID Numbers: 264D; PROA3001
Study Start Date:
Record last reviewed: November 1998
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002195
Other Hiv Infections Studies:
1. A Study of ddC in Patients with AIDS or Advanced AIDS-Related Complex (ARC) Who Have Not Had Success with Zidovudine (AZT)
2. A Multi-Center, Open-Label, Ascending, Multiple Oral dose, Safety, Tolerance and Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Patients With Acquired Immune Deficiency Syndrome (AIDS) or AIDS-Related Complex (ARC)
3. The Safety and Effectiveness of Clarithromycin in the Prevention of Mycobacterium avium Complex (MAC) Infection in HIV-Infected Patients
4. Safety of Tenofovir Disoproxil Fumarate (TDF) in HIV Infected Pregnant Women and Their Infants
5. A Study of Didanosine Use Alone or in Combination with Zidovudine in Infants Exposed to or Infected with HIV
Related Studies:
Other HIV Infections Clinical Trials
Other Tennessee Clinical Trials
Other Memphis Clinical Trials
A Study of Retrovir and Epivir Alone or in Combination with 141W94 in HIV-Infected Patients
|
|
|
|
|
|
|
|
